Clinical Profile of Cardiac Involvement in Danon Disease: A Multicenter European Registry. by Lotan, Dor et al.
 1 
Clinical Profile of Cardiac Involvement in Danon Disease: A Multicenter European 1 
Registry. 2 
          Dor Lotan 1*, Joel Salazar-Mendiguchía2*, Jens Mogensen3, Aris Anastasakis 4, Juan 3 
Kaski5,$, Pablo Garcia-Pavia 6,*, $, Iacopo Olivotto 7, Philippe Charron 8,$, Elena 4 
Biagini 9 , Anwar Baban 10, Giuseppe Limongelli 11,$,  Katie Anne Walsh12 , Yishay 5 
Wasserstrum1,  Joe Galvin12, Esther Zorio13, Attilio Iacovoni 14 , Lorenzo Monserrat15,  6 
Paolo Spirito 16,  Maria Iascone 14# and Michael Arad1# 7 
1 Leviev Heart Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv 8 
University, Tel Aviv, Israel. 9 
2 Cardiomyopathy Unit- Hospital Universitari de Bellvitge, Barcelona, and Health in Code, 10 
Spain . 11 
3  Department of Cardiology, Odense University Hospital, Denmark.   12 
4  Unit of Inherited Cardiovascular Diseases- 1st Dpt of Cardiology - University of Athens, 13 
Greece . 14 
$ European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart 15 
(ERN GUARDHEART; http://guardheart.ern-net.eu). 16 
5 Inherited Cardiovascular Diseases Unit - Great Ormond Street Hospital, London UK.  17 
6 Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, 18 
CIBERCV, Madrid, Spain . 19 
* Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcón, Spain. 20 
7 Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy . 21 
8 Faculty hospital Pitié-Salpêtrière, Paris, France. 22 
9 Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Alma Mater 23 
Studiorum, University of Bologna, Bologna, Italy . 24 
10 Medical and Surgical Department of Pediatric Cardiology, Bambino 25 
Gesù Children  Hospital – IRCCS, Rome, Italy. 26 
11 Monaldi Hospital, AO Colli, Second University of Naples, Naples, Italy. 27 
12 Department of Cardiology and University College Dublin School of Medicine, Mater 28 
Misericordiae University Hospital, Dublin, Ireland 29 
13 Hospital Universitario La Fe, Valencia, Spain 30 
14  Molecular Genetics Laboratory, A.O. Papa Giovanni XXIII, Bergamo, Italy.  31 
15 Health in Code, Hospital Marítimo de Oza, As Xubias, A Coruña (Spain). 32 
 2 
16 Hypertrophic Cardiomyopathy Center, Policlinico di Monza, Monza, Italy 1 
 2 
 Equal contribution      # Equal contribution 3 
Corresponding Author:  Michael Arad MD 4 
    Associate Professor of Cardiology 5 
      Leviev Heart Institute, Sheba Medical Center, Ramat Gan and 6 
Sackler School of Medicine, Tel Aviv University, Israel  7 








Danon disease is a rare X-linked dominant metabolic disorder leading to cardiomyopathy, 5 
proximal myopathy and intellectual disability. To date, no specific therapy is available to 6 
prevent disease progression. The purpose of this registry is to generate a comprehensive 7 
picture of the prevalence, clinical presentation and outcome of patients with Danon disease 8 
evaluated in the cardiomyopathy centers over Europe.  9 
 Methods and Results 10 
Data was retrospectively collected in cardiology centers over Europe using a consensus 11 
datasheet. Clinical and genetic data were analyzed. The cohort comprised 65 patients; 46% 12 
(N = 30) were males and 54% (N = 35) were females, including 27 affected and 8 gene 13 
carriers. The age at diagnosis was birth to 42 years in males and 2 to 65 years in females 14 
(p<0.01). Mean age at first heart failure hospitalization was lower 18 ± 6 in males vs. 28 ±17 15 
in females, p<0.003.  Cardiac involvement was seen in 55 of our patients (96%). Left 16 
ventricular (LV) hypertrophy was reported in 73% of males and in 74% of the affected 17 
females with an average left ventricular wall thickness of 20±8 and 17±6 mm respectively. 18 
Reduced LV function was reported in 30% males and 59% of females with mean LVEF of 19 
34±11% and 28±13% respectively. The principal cause of death was heart failure (n=XX). 20 
Systolic LV dysfunction was the main predictor of adverse outcome.  Sixteen (28%) of the 21 
patients underwent heart transplantation or received a left ventricular assist device (LVAD). 22 
There was a 62% (5/8) mortality in males receiving heart transplant or LVAD within 1 year 23 
after the procedure. 24 
Conclusion 25 
Comentado [PGP1]: This is mean LVEF of the entire 
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 4 
DD presents approximately 10-20 years earlier in  males than females and runs a highly 1 
malignant course in both genders. Cardiac manifestations are comparable among genders 2 
with high individual variability. Extra-cardiac manifestations are  uncommon  in females, 3 
making their clinical diagnosis unlikely.  4 
Keywords: Danon Disease, cardiomyopathy , arrhythmia, heart failure, heart transplantation  5 
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Introduction  1 
Danon disease is a rare X-linked dominant metabolic disorder described first by Danon et al 2 
in 1981 in two unrelated 16-year-old boys with mental retardation, cardiomegaly, proximal 3 
myopathy and intellectual disability (1). In 1940, Antopol et al (2) reported two brothers with 4 
cardiac hypertrophy caused by glycogen storage in cardiac and skeletal muscles, leading to 5 
death in the second decade of life. This is apparently the earliest description of this rare and 6 
lethal condition. Danon’s, also termed Glycogen Storage Disease IIb, is caused by LAMP2 7 
mutations is a. Given the role of LAMP2 in lysosomal fusion (3), LAMP2 deficiency leads to 8 
failure to complete the final step of the autophagic process, where digestion of aged cellular 9 
contents (inc. glycogen) and organelles takes place. Inability to remove aged mitochondria 10 
(mitophagy) leads to mitochondrial dysfunction, energetic deficiency and oxidative stress (4–11 
6). Although Danon is a multisystem disease, cardiac manifestations constitute the main 12 
cause of morbidity and mortality. In recent years, the disease has been diagnosed with higher 13 
frequency due to the introduction of modern genetic techniques. To date, no specific therapy 14 
is available to prevent disease progression. 15 
International registries are crucial in studying orphan diseases to properly define the natural 16 
history, outcome of interventions and potentially enroll patients in therapeutic trials. The 17 
purpose of this registry is to generate a comprehensive picture of the prevalence, clinical 18 
presentation and outcome of patients with Danon disease evaluated in the cardiomyopathy 19 
centers over Europe, Our data should help improve the recognition and diagnosis of this 20 
complex disease, allowing to optimize the medical care of patients and families. 21 
 Methods 22 
The study is a collaborative effort of a team of expert cardiologists across Europe who 23 
operate within a framework specialized centers dedicated to cardiomyopathies and inherited 24 
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 6 
heart diseases.  Data was collected retrospectively using a consensus datasheet  and 1 
interpreted by the primary investigators. All patients had to be evaluated and followed by a 2 
cardiologist in the participating center. Patient  management and data collection  were 3 
conducted according to local regulations.  4 
The diagnosis of Danon disease was based of clinical manifestations and documentation of a 5 
mutation in the LAMP2 gene. Carrier status (observed only  in females) was defined by 6 
confirmation of a disease-causing mutation in the absence of any (cardiac or extracardiac) 7 
evidence of disease, and the presence of  one or more affected first-degree family members. 8 
Patients and carriers were classified according to gender, age of diagnosis/presentation, 9 
clinical features at the time of first evaluation and cardiovascular events during follow-up. 10 
Mutations were classified according to their principal type: mutations affecting a Splice-site, 11 
Frameshift, Non-sense mutations, or a Major deletion. Patient follow-up and management 12 
were conducted according to the local medical practice.  The data on genetic and clinical 13 
profile included in the database were collected by the assigned cardiologist. The presented 14 
data  includes clinical, electrocardiographic and echocardiographic features at initial 15 
evaluation (as reported by the participating centers) as well as hard outcome events such as 16 
cardiac arrest, device implantation, heart transplantation and death.  17 
Statistical analysis  18 
Variables were described according to their properties. Categorical variables are reported in 19 
frequencies and percentages, and significance was assessed using the chi-square test or 20 
Fischer's exact test. Continuous variables with a normal distribution were reported as mean 21 
and standard deviation values, and significance was assessed using the t-test. Continuous 22 
variables that did not have a normal distribution were reported as median and interquartile 23 
range (IQR, 25th-75th percentiles) values, and significance was assessed using non-24 
 7 
parametric Mann-Whitney U test.  All statistical tests were 2-sided, and a p value of less than 1 
0.05 was considered significant.  In the adjusted analysis, potential covariates were analyzed 2 
in univariate logistic regression models, and variables found to have a p < 0.1 were included 3 
in the adjusted model. The statistical analysis was carried out with the use of R version 3.6.1 4 
software (The R Foundation) and R-studio 1.2.5001 (R Studio, Inc.). 5 
A comprehensive bibliographical search (PubMed, Web of Science and Google Scholar) 6 
collected all available clinical information of families and individuals who carried LAMP2 7 
mutations. Curves illustrating the cumulative percentage of clinically affected carriers of 8 
pathogenic variants in LAMP2 (i.e. Danon disease) against age as well as Kaplan-Meier 9 
survival curve were constructed to correspond to patients from this project, and  to all 10 
patients in Health in Code’s database.   11 
 12 
Results 13 
Epidemiology and Genetics 14 
Of 65 patients included, 46% (N = 30) were males and 54% (N = 35) were females including 15 
27 affected and 8 gene carriers (Table 1). Twenty nine families from 8 countries over Europe, 16 
harboring 25 different mutations in the LAMP2 gene, including 9 frameshift, 8 nonsense, 7  17 
affecting a splice-site, and one major deletion. Among the clinically affected patients, the 18 
most common variants were mutations affecting a splice site (Suppl, Table 1). Mutations 19 
appeared to arise de novo in 13 individuals. Family history of sudden death was reported in 20 
13/29 (45%) representing a majority among those with familial disease. There was no 21 
significant difference when comparing nonsense  to frameshift and splice-site mutations 22 
regarding age of diagnosis and age of death or heart transplant no was found.  23 
 8 
There was a significant difference in the age at diagnosis: mean 13 years in males (ranging 1 
from birth to 42), compared to 36 years in the affected females (range2-65 yr., p<0.01). The 2 
mean age of  female carriers was 31  years (range 2-46). The  age of first heart failure 3 
hospitalization was also lower in males compare to females (18 ± 6 vs 28 ±16.6,p<0.003, 4 
Figure 1).  5 
Clinical Manifestations by Gender  6 
Cardiac involvement was seen in 55 of our patients (96%). Cardiomyopathy was present in 7 
all the affected except two of the males  (Table 2). Left ventricular hypertrophy (wall 8 
thickness ≥13 mm) was reported in 73 % (n=22) of males and in 74% (n=20) of females with 9 
an average left ventricular wall thickness of 20±8 and 17±6 (mm) respectively. Hypokinetic 10 
(EF <50%) cardiomyopathy (dilated or hypertrophic) presented in 30% (n=12) of males and 11 
59% (n=16) of females with mean ejection fraction of 34±11% and 28±13% respectively.  12 
Electrophysiological abnormalities such as extreme ECG voltage, Wolf Parkinson White 13 
(WPW) and early atria-ventricular block are considered Red Flags  suggesting a possibility of 14 
metabolic disease being the cause of cardiomyopathy (7). In our cohort, conduction 15 
abnormalities such as WPW pattern were quite common  in males (50%,n=15) and females 16 
(41%, n=11, Table 2). Atria-ventricular block was most commonly of the 1st degree. 17 
Advanced atria-ventricular block was reported in 15% (n=4) in males and 14% (n=4) of the 18 
affected females. Paroxysmal or permanent atrial fibrillation was more common in females 19 
(55% vs 27% in males, p=0.02). Lethal ventricular tachyarrhythmia’s (sustained ventricular 20 
tachycardia, ventricular fibrillation or cardiac arrest) were reported in males and females. A 21 
total of 39 (68%) patients received device therapy (permanent pacemaker, ICD, or CRT-D, 22 
Table 2).  The most common indication for ICD implantation in the normal  EF group was 23 
primary prevention. Two patients received ICD after aborted ventricular fibrillation and 2 24 
 9 
ICD after a documented episode of sustained ventricular tachycardia.  Among patients within 1 
the reduced EF group, 7  had ventricular tachycardia early after the diagnosis of Danon 2 
disease while 4 reported a recorded lethal ventricular arrhythmia and appropriate shock 3 
therapy during the follow-up. 4 
 Other Clinical Features  5 
Extracardiac manifestation seen in Danon disease aggravate the morbidity and may constitute 6 
a clue to the diagnosis. Muscular involvement in a form of myopathy was clinically 7 
significant in 60% (n=18) of males but in only 3% (n=1) in females (p<0.001). Elevated 8 
creatine phosphokinase (>2 times normal limit) was reported in 80% (n=24) of males and 9 
none of the women (p<0.001). Elevated liver transaminases enzymes were found in 83% 10 
(n=25) of males and 6% (n=2) in females (p<0.001). Pronounced learning, neurological or 11 
psychiatric problems were quite common in 73% (n=22) in males but rare in 9% (n=3) of 12 
females (p<0.001). Clinically manifest visual involvement was equally uncommon in both 13 
gender group (Figure 2).  14 
Mortality and Prognosis  15 
In our cohort, among 57 clinically affected, 16 patients (27%) underwent heart 16 
transplantation or received a left ventricular assist device (LVAD). Eight were males (6 17 
underwent heart transplantation and 2 had LVAD implanted,  mean age 23±8 yr.) and eight 18 
were females (all underwent heart transplantation at mean age 29±9  yr, p=0.13, Figure 1).  19 
Seventeen patients (30%, 11 males and 6 females) died over a total follow up of 350 patient- 20 
years, including  5 heart transplant/assist device male patients. The mean age of death among 21 
men were 23±19 and 45±18 in females (p=0.02). The leading cause of death was heart 22 
failure, that was seen in 10 patients (59%). Sudden cardiac death occurred in 2 female 23 
 10 
patients who had no ICD.  Four died from malignant ventricular arrhythmias despite having 1 
an implanted cardioverter-defibrillator (ICD).   2 
Five male heart transplant (n=4) /LVAD recipients (n=1) died, all within 1 year after the 3 
procedure, comprising a 62% mortality.   No death was reported among females receiving 4 
heart transplant.  5 
Overall prognosis was independent of gender. In a univariate analysis, patients who had a terminal 6 
event (death, assist device or heart transplantation) were older at diagnosis and at the time of 7 
evaluation (Table 3 and suppl. Table 2). Reduced left ventricular systolic function has associated with 8 
mortality (71% vs. 31%, p=0.002), as were AV block >1st degree (25% vs. 3%, p=0.025) and atrial 9 
fibrillation (56% v. 28%, p=0.034).  10 
In an adjusted logistic model, which includs variables that were significant in a univariate analysis, 11 
only hypokinetic left ventricle remained a significant predictor of mortality.  This result did not 12 
change when we included also age and gender in the multivariate model (OR 3.85, 95%CI 1.06-14.96, 13 
p=0.043, Table 3). 14 
Disease Expression and Survival Curves 15 
We then constructed the curves of cumulative incidence of disease expression and survival by 16 
age. We then compared our cohort to all DD cases reported in the literature (Figures 3a and 17 
3b comprising data from 105 males and 90 females). There is no notable difference between 18 
the curves indicating that the data provided in the current cohort is highly representative of 19 
DD population in either males or females.   20 
 21 
Discussion  22 
Danon Disease is a rare multisystem lysosomal storage disease that is transmitted as X-23 
Linked with dominant inheritance trait. It is caused by a dysfunction or deficiency of the 24 
Comentado [PGP4]: Causes of death? 
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lysosome-associated membrane protein-2 (LAMP-2) that disrupts autophagy, leading to an 1 
impaired fusion of lysosomes to autophagosomes and biogenesis of lysosomes. Due to X 2 
linked dominant inheritance pattern, hemizygous males transmit the trait to all daughters but 3 
not to their sons. Heterozygous females usually suffer from milder and variable symptoms 4 
due to different patterns of X chromosome inactivation. Transmission of disease from mother 5 
to daughter is compatible with an X-linked dominant inheritance and is pronounced when the 6 
protein product of the wild-type allele remains below the normal threshold level (8). Danon 7 
disease typically occurs through LAMP2 protein deficiency but protein malfunction may 8 
explain some cases. It was actually proposed to measure LAMP2 in lymphocytes  as a 9 
screening tool for DD. Different gene defects may have various effects on splicing and 10 
protein expression, but we did not find major differences in disease presentation among the 11 
mutation types (Suppl. table 1).  12 
The real prevalence of DD in the population is unknown.  Widespread screening  in Genetic 13 
centers using multiple parallel /next generation sequencing (NGS) led to successful detection 14 
of LAMP-2 mutations among cardiomyopathy and myopathy  patients  implying a unique 15 
(often unexpected) diagnosis with grave medical and therapeutically consequences (9,10). 16 
Certain reports using NGS in highly selected cohorts from specialized referral centers has 17 
showed disease frequency of 4-6% among children with hypertrophic cardiomyopathy 18 
(HCM) (11,12), and 0.7- 4% among adults with HCM (9,13,14). The prevalence may be even 19 
higher such as 6-8% among adults with concentric HCM (15), 17-30% among patients with 20 
HCM and pre-excitation on ECG (13,16,17). It was reported to be as high as 33% among 21 
patients with vacuolar myopathy and HCM (18),  suggesting that in pediatric cardiology DD 22 
is one of the leading causes of such clinical constellation (19,20). Wide application of gene 23 
sequencing also allowed identifying DD among women with cardiomyopathy, including 24 
those with early conduction system disease and a postpartum presentation. In contrast, no 25 
 12 
Danon disease patient was identified by NGS screening among 72 children with idiopathic 1 
dilated cardiomyopathy (11).  2 
The diagnosis of Danon is very uncommon even in cardiomyopathy clinics and this entity 3 
may not be familiar to many general cardiologists. Among 17704 studies of NGS on index cases 4 
by Health in Code laboratory (A’Coruna Spain, Lorenzo Monserrat personal communication) that 5 
included more than 10000 probands with cardiomyopathy, the evaluation of LAMP2 identified 18 6 
pathogenic or likely-pathogenic variants. 7 
Due to the low prevalence of the disease, most data available to date is based on small case 8 
reports and single center studies that may not represent the possible heterogeneity between 9 
families and ethnicities across the globe. Others investigators constructed datasets by 10 
collecting  case series or web-based registries. Recently, Cenacchi et al.(20)  reviewed all 11 
published cases of DD to date, included 332 patients reported from case reports and small 12 
series as well as  186 patients from large series. Single center studies, such as Sugie et al. 13 
(21,22) reported a total of 77  Japanese patients.  Boucek et al.(23)  reported 82 patients 14 
widely dispersed across four continents, of whom only 44 had  clinical finding 15 
reported. López-Sainz et al. recently reported on 27 patients collected from all over 16 
Spain.(ref)  17 
Our study represents an attempt to establish a European registry of Danon disease conducted 18 
by leading cardiomyopathy clinics across Europe. Due to disease complexity and the variable 19 
clinical course, follow up data on these patients is often incomplete. We collected data from 20 
cardiomyopathy experts who examined these patients, by using  a simple questionnaire 21 
designed to target the principal points while attempting to minimize missing data. Our data 22 
on 57 genetically and clinically affected patients from Europe demonstrate a high prevalence 23 
of cardiac disease both in men (93%) and in women (100%). While there were certain 24 
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differences among the genders, the main difference was in the age of presentation, but less so 1 
in the specific features of the cardiac phenotype or disease complications,  While the 2 
approximate delay in  disease expression in women was by approximately 20 years compared 3 
with men, the age and mode of presentation in females was highly variable  4 
A comparable proportion of females and males presented with LVH and/or systolic 5 
dysfunction. Further, the wall thickness and the ejection fraction were similar among the 6 
genders. This finding contradicts previous reports suggesting that females mostly present 7 
with DCM compared to massive HCM in males (24). Females had a similar prevalence of 8 
ventricular arrhythmia but more atrial fibrillation, similar to smaller series reported 9 
previously (25). Sudden cardiac death among 2 female patients with no ICD is an alarming 10 
notion of their arrhythmic risk which may not necessarily be predicted by massive 11 
hypertrophy or reduced ejection fraction. 12 
Extracardiac manifestations were common in males but rather non abundant in females, 13 
making the clinical diagnosis in affected women (in the absence of family history) nearly 14 
impossible. In depth investigations of visual and psycho-cognitive testing may disclose subtle 15 
abnormalities in the affected females but those are rarely clinically pronounced to draw 16 
attention in the early stages of the disease. Previous study reported that  IQ and cognitive 17 
abilities were assessed by standardized cognitive measurements, most of them are not shown 18 
to have intellectual disability/mental retardation but rather milder cognitive (eg, executive 19 
functioning) deficits (11,26). These findings emphasize the importance of gene testing in 20 
women with what appears to be idiopathic cardiomyopathy.  21 
Reduced left ventricular systolic function was the only independent predictor of prognosis in 22 
our study. This finding corresponds to the prevailing notion that the hallmark of cardiac 23 
Danon disease is a progressive myocardial fibrosis commencing in   combined systolic and 24 
 14 
diastolic failure as well as a substrate for ventricular arrhythmia. While novel therapies are 1 
been developed, contemporary therapies to attenuate fibrosis might be useful to modify the 2 
course of cardiomyopathy.   3 
Our results draws attention to a poor prognosis of heart transplant in males with DD. While 4 
often no other option is left, the transplant clinic should be prepared to deal with 5 
neuromuscular complications (eg. post-transplant myopathy) and psychiatric issues which 6 
may occur in the peri- and postoperative period.  While there are numerous case reports of 7 
successful heart transplantation in DD males,  unlucky cases are less likely to be reported. 8 
Prospective  cohorts are therefore needed to address this issue   9 
Our data should serve as a basis to better understand the spectrum of clinical presentation and 10 
natural history of the disease and to facilitate diagnosis. Timely clinical and genetic diagnosis 11 
allow to plan observational and interventional  research projects focused on treating this 12 
complex disease (30).  13 
Limitations and perspectives 14 
This is an observational cohort with a limited follow up. Given its retrospective nature, we 15 
had a difficulty to define the rate of disease progression as well as arrhythmia events over 16 
time. While DD heart is characterized by a progressive fibrosis we did not have an MRI data 17 
to assess its relationship to the clinical events. Our findings and conclusions should stimulate 18 
prospective observational studies to explore the critical turning points along the course of the 19 
disease(27,28) Danon disease is extremely rare and therefore at disadvantage in a stride for 20 
specific therapy. Nevertheless, attempts to develop gene therapy or (possibly) protein therapy 21 
are underway(29). Meanwhile  lifestyle intervention and therapies and should be assessed in 22 
a longitudinal fashion to optimize data collection and disease management (30).  23 
 24 
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Legends  3 
Table 1:  Title- Geographic distribution of patients and families 4 
The distribution of Danon disease patients by countries involved in our registry, 5 
number of families and patients with gender differentiation. Last column refer to 6 
number of families detected from each country  with a history of sudden cardiac death.  7 
SCD, sudden cardiac death  8 
Table 2: Title- Cardiac Manifestations among the affected patients  9 
 Cardiac manifestations and device implanted among the affected Danon patients are 10 
presented by gender.  11 
 LVH, Left ventricular hypertrophy (defined by  , WPW,Wolf Parkinson white, VT, 12 
Ventricular tachycardia, VF, Ventricular fibrillation, ICD, Implantable cardioverter-13 
defibrillator, CRTD, cardiac resynchronization therapy with defibrillator. 14 
†LVH, LV wall thickness (≥13 mm), * Hypokinetic cardiomyopathy, LVEF<50%, # 2 15 
patient expired prior to LVEF assessment 16 
Table 3: Title- Regression analysis to characterize patients with a terminal event 17 
 The table presents the Results of logistic regression analysis. Potential variables were 18 
analyzed in univariate logistic regression models. Variables found to be significant at p 19 
< 0.05, were included in the multivariate model adjusted for age of diagnosis and 20 
gender.  21 




Figure 1:  Title: Age at  first  heart failure  hospitalization, heart transplantation  or death  3 
 Figure shows mean age of Danon patients disease, by gender, presented with their first 4 
heart failure hospitalization, age of death and age of heart transplant or assist device 5 
implantation. Males were presented earlier with their first heart failure hospitalization 6 
compared to females  (18±6 vs 28±16.6, p=0.003). Mean age of heart transplantation 7 
or assist device as well as age of death  was lower in males  (23±8 vs. 29±9 in females, 8 
p=0.13 and 23±19 vs.45±18, p=0.02 respectively).  9 
Figure 2: Title- Extra cardiac manifestations 10 
 The non-cardiac manifestations in Danon  patients are illustrated by gender and their 11 
prevalence in percent.  Clinical myopathy, elevated creatine phosphokinase (>2 times 12 
normal limit), elevated liver  enzymes and neurobehavioral problems (learning, 13 
neurological or psychiatric issues)) were more common in males than in females 14 
(p=0.001). The numbers above the bars refer to the absolute number of patients.   CPK, 15 
creatine phosphokinase  16 
Figure 3: Age of presentation and survival of Danon patients 17 
Figure 3a: Title- Age of clinical presentation  among LAMP2 mutation carriers 18 
  Figure shows cumulative percentage of carriers of pathogenic variants in LAMP2 who 19 
were clinically diagnosed with the disease (i.e. Danon disease) against age and and 20 
according to gender. Two groups are depicted: blue and green lines correspond to 21 
patients from this project, whereas yellow and red lines belong to patients in Health in 22 
Code’s database (which includes patients from the scientific literature as well as from 23 
 22 
Health in Code’s research).  Both groups (Danon project and Health in Code’s 1 
database) show similar age-dependence of diagnosis. Males are diagnosed at an earlier 2 
age, with up to 30% of male carriers being diagnosed with the disease during the first 3 
decade of life, whereas 30% of females are diagnosed from their mid-third decade of 4 
life onwards.  All male patients received a clinical diagnosis of Danon disease in this 5 
project, whereas almost 20% of females remained undiagnosed at last available 6 
follow-up. 7 
Figure 3b: Title- Survival free of cardiovascular death in Danon disease patients 8 
 Figure shows the Kaplan-Meier survival curve free from cardiovascular death in 9 
carriers of pathogenic variants in LAMP2 belonging to this research (Danon project) 10 
compared with findings from Health in Code’s database. Both groups are divided 11 
according to gender. Male patients may present with events early in life, with a steep 12 
decline in survival from the second decade of life onwards. Female carriers present 13 
with events later in life, mainly from the fourth decade of life onwards.  14 
See supplemental Figure 1  for percentage of events according to gender and age.   15 
Supplement table 1: Title- Age of diagnosis and age of death by mutation type 16 
 Mutations found in this cohort include frameshift, nonsense, splicing and 1 major 17 
deletion. We compared mean age of diagnosis and death or terminal event  between 18 
males and females by mutation type.   19 
Terminal event, Death, assist device or heart transplant during the follow-up 20 
Supplemental table 2: Title- Predictors of terminal events among the affected patients  21 
 We compared surviving patients  with those who had a terminal events which include 22 
death, heart transplantation or left ventricular assist device implantation. Patients with 23 
 23 
terminal event had reduced ejection fraction, significantly atrio-ventricular block (>1st 1 
degree AV block ) and atrial fibrillation.  2 
LV, left ventricular AV, Atrioventricular 3 
4 
 24 
Text tables:  1 







Families with a 
history of SCD 
(n)  Affected Carrier 
Italy 13 18 10 8  5 
Spain 5 11 3 7 1 1 
Israel 1 9 4 2 3 1 
Denmark 2 5 2 3  1 
United Kingdom 2 4 3 0 1 1 
Greece 2 4 3 1  1 
France 2 3 2 0 1 1 
Ireland 2 11 3 6 2 2 
Total 29 65 30 27 8 13 
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Age of diagnosis (Mean ± SD) 13±9 36±15 <0.001 
Age of last follow up 19±12 38±16 <0.001 
Cardiomyopathy – all (no, %) 28 (93%) 27 (100%) 0.49 
Left ventricular wall thickness -no.(%)   0.49 
        No LVH   8 (27%) 7 (26%)  
        LVH †    22 (73%) 20 (74%)  
        LV thickness Mean ± SD (mm) 20±8 17±6 0.28 
Left Ventricular function no. (%)    
        Normal  18 (60%) 9 (33%) ** 0.071 
        Hypokinetic * 12 (30%) 16 (59%) 0.06 
              Mean ± SD (mm) 34±11 28±13 0.05 
Electrophysiological – no. (%)    
        WPW 15 (50%) 11 (41%) 0.48 
        Atrioventricular Block    1 
                 I 5 (17%) 4 (15%)  
                 II 2 (7%) 2 (7%)  
                 III 2 (7%) 2 (7%)  
         Atrial Fibrillation  8 (27%) 15 (55%) 0.02 
         Sustained VT 6 (20%) 4 (15%) 0.73 
         VF / ARREST 4 (13%) 2 (7%) 0.67 
Device Therapy – no. (%)    0.89 
        Permanent pacemaker 5 (17%) 7 (26%)  
         ICD 11 (37%) 10  (37%)  
        CRT-D 3 (10%) 2 (7%)   
† LVH, LV wall thickness (≥13 mm) 
* Hypokinetic cardiomyopathy, LVEF<50% 























Age of diagnosis 1.02 0.99-1.06 0.16 NA NA NA 
Atrial fibrillation 3.28 1.10-10.40 0.04 1.96 0.51-7.41 0.315 
AV block >1st 
degree 9.33 
1.50-
181.54 0.04 6.52 0.89-135.74 0.109 
Female gender 1.23 0.43-3.52 0.7 NA NA NA 
Hypokinetic LV 5.56 1.85-18.24 0.003 3.85 1.06-14.96 0.043 
LV thickness 
>13mm 2.07 0.61-7.70 0.25 NA NA NA 
Adjusted regression analysis, potential covariates were analyzed in univariate logistic regression models, 
and variables found to have a p < 0.01 were included in the adjusted model.  
Terminal event; Death, assist device or heart transplant during the follow-
up    
 2 
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Figure 3a: Age of clinical presentation  among LAMP2 mutation carriers 2 
 3 
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Figure 3b: Survival free of cardiovascular death in Danon disease patients 1 
 2 
  3 
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Age of diagnosis 
Age of death or heart 
transplantation 
Male  Female Male  Female 
Frameshift 9 13 9.9 (±10) 36.2 (±14.3) 17.8 (±3.3) 23.3 (±5.0) 
Nonsense 8 18 
9.8 
(±8.8) 32.1 (±15.9) 23.0 (±8.4) 36.4 (±13.9) 
Splicing 7 24 13 (±9.4) 35.2 (±13.4) 25.5 (±6.5) 44.1 (±18.1) 
Major deletion 1 2 5 37     
 4 




Supplemental table 2: Predictors  of terminal events among the affected patients  
Characteristics 
Alive   (n=29) 
Terminal event*  
(n=28)  p 
Age of diagnosis (years) 16.0 (6.0-36.0) 21.0 (16.0-41.2) 0.06 
Male (no., %) 16 (55%) 14 (50%)  
Female (no., %) 13 (45%) 14 (50%) 0.696 
Left ventricular hypertrophy (no., %) 20 (69%) 23 (82%) 0.358 
LV thickness, >13mm (no., %) 20 (69%) 23 (82%) 0.358 
Hypokinetic  (LVEF<50%) (no., %) 9 (31%) 20 (71%) 0.002 
Wolf parkinson white (no., %) 14 (48%) 12 (43%) 0.681 
AV block, >1st degree (no., %) 1 ( 3%) 7 (25%) 0.025 
Sustained ventricular tachycardia (no., %) 5 (17%) 5 (19%) 1 
Atrial fibrillation (no., %) 8 (28%) 15 (56%) 0.034 
*Terminal event: Death, Heart transplantation or left ventricular assist device implantation 
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